

CORRECTION

Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study

Sebastiano Buti¹ · Maddalena Donini² · Melissa Bersanelli¹ · Alessia Gattara¹ · Francesco Leonardi¹ · Rodolfo Passalacqua²

Published online: 28 May 2018
© The Author(s) 2018

Correction to:
Drugs R D <https://doi.org/10.1007/s40268-017-0209-5>

In the Original Publication of the article, In Introduction part, 7th line, the value “5–100 nM” has been published incorrectly. The correct value should read as “Plasma concentration of 50–100 ng/ml”. In the Original Publication of the article, page 591, Table 2 has been published incorrectly. The corrected table is shown below:

Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Table 2 Delivered treatment, dose reductions and interruptions

	Sunitinib 4/2 schedule	Sunitinib modified schedule
Median time from start to switch, months (range)	2.9 (1.4–16.5)	–
Median duration of treatment after switch, months (range)	–	9.2 (0.5–32.4)
Mean actual daily dose intensity, mg (range)	46.1 (20.8–50.0)	44.3 (17.9–71.8)
Mean relative dose intensity, % (range)	92.3 (42–100)	88.7 (36–144)
Total cycles, number	88	164
Median cycles, number (range)	2 (1–11)	5 (1–20)
Patients with a dose reduction, number (%)	3 (12)	3 (12)
Patients with a dose interruption, number (%)	7 (28)	12 (48)
Number of dose interruptions corrected for number of cycles (%)	0.10 (10)	0.11 (11)
Patients still on treatment, number (%)	–	2 (16)

The original article can be found online at <https://doi.org/10.1007/s40268-017-0209-5>.

✉ Melissa Bersanelli
bersamel@libero.it

¹ Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43126 Parma, Italy

² Oncology Unit, Oncology Department, ASST Ospedale di Cremona, Cremona, Italy